Krzysztof Mrzek

List of Publications by Citations

102 papers	11,485 citations	53 h-index	105 g-index
105 ext. papers	12,606 ext. citations	6.2 avg, IF	5.52 L-index

#	Paper	IF	Citations
102	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood*, **2002**, 100, 4325-36	2.2	1287
101	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology*, **2010**, 28, 2348-55	2.2	599
100	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. *Journal of Clinical Oncology*, **2006**, 24, 3904-11	2.2	534
99	Cytogenetics in acute leukemia. *Blood Reviews*, **2004**, 18, 115-36	11.1	506
98	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. *Blood*, **2007**, 109, 431-48	2.2	452
97	MicroRNA expression in cytogenetically normal acute myeloid leukemia. *New England Journal of Medicine*, **2008**, 358, 1919-28	59.2	386
96	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. *Journal of Clinical Oncology*, **2012**, 30, 4515-23	2.2	310
95	Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. *Journal of Clinical Oncology*, **2005**, 23, 5705-17	2.2	272
94	Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology*, **2010**, 28, 596-604	2.2	268
93	TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology*, **2011**, 29, 1373-81	2.2	266
92	Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. *Journal of Clinical Oncology*, **2008**, 26, 5078-87	2.2	266
91	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. *Blood*, **2006**, 108, 63-73	2.2	253
90	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. *Blood*, **2008**, 111, 1552-9	2.2	221
89	The prognostic and functional role of microRNAs in acute myeloid leukemia. *Blood*, **2011**, 117, 1121-9	2.2	218
88	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. *Blood*, **2011**, 118, 6920-9	2.2	216
87	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. *Journal of Clinical Oncology*, **2012**, 30, 742-50	2.2	215
86	Acquired copy number alterations in adult acute myeloid leukemia genomes. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 12950-5	11.5	209

85	WilmsStumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. *Journal of Clinical Oncology*, **2008**, 26, 4595-602	2.2	200
84	Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology*, **2005**, 23, 9234-42	2.2	199
83	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. *Journal of Clinical Oncology*, **2012**, 30, 3109-18	2.2	195
82	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 18679-84	11.5	181
81	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*, **2010**, 116, 3622-6	2.2	179
80	Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. *Journal of Clinical Oncology*, **2004**, 22, 1087-94	2.2	166
79	High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. *Journal of Clinical Oncology*, **2007**, 25, 3337-43	2.2	165
78	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. *Blood*, **2008**, 111, 5371-9	2.2	159
77	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology*, **2010**, 28, 5257-64	2.2	155
76	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. *Nature Genetics*, **2016**, 48, 1481-1489	36.3	145
75	Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. *Journal of Clinical Oncology*, **2013**, 31, 2086-93	2.2	141
74	Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 3915-20	11.5	141
73	Clinical importance of cytogenetics in acute myeloid leukaemia. *Best Practice and Research in Clinical Haematology*, **2001**, 14, 19-47	4.2	140
72	Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. *Journal of Clinical Oncology*, **2009**, 27, 3198-204	2.2	135
71	Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. *Journal of Clinical Oncology*, **2014**, 32, 548-56	2.2	119
70	Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. *Seminars in Oncology*, **2008**, 35, 365-77	5.5	114
69	Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. *Blood*, **2006**, 108, 1677-83	2.2	108
68	Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. *Journal of Clinical Oncology*, **2005**, 23, 482-93	2.2	106

67	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*, **2010**, 116, 5660-9	2.2	99
66	Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. *Journal of Clinical Oncology*, **2008**, 26, 4934-9	2.2	97
65	Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. *Current Opinion in Hematology*, **2005**, 12, 68-75	3.3	95
64	Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. *Hematology American Society of Hematology Education Program*, **2006**, 2006, 169-77	3.1	91
63	Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. *Journal of Clinical Oncology*, **2004**, 22, 2410-8	2.2	89
62	Cytogenetics and molecular genetics of acute lymphoblastic leukemia. *Hematology/Oncology Clinics of North America*, **2009**, 23, 991-1010, v	3.1	88
61	Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. *British Journal of Haematology*, **2007**, 137, 387-400	4.5	88
60	Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. *Journal of Clinical Oncology*, **2001**, 19, 2482-92	2.2	86
59	Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. *Blood*, **2007**, 109, 5164-7	2.2	85
58	Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. *Genes Chromosomes and Cancer*, **2002**, 34, 137-53	5	76
57	Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. *Hematology/Oncology Clinics of North America*, **2011**, 25, 1135-61, vii	3.1	74
56	Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*, **2010**, 116, 788-92	2.2	71
55	Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. *Current Opinion in Oncology*, **2008**, 20, 711-8	4.2	68
54	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. *Blood*, **2012**, 120, 249-58	2.2	58
53	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. *Blood Advances*, **2018**, 2, 1645-1650	7.8	58
52	Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. *Current Opinion in Hematology*, **2007**, 14, 106-14	3.3	57
51	Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. *British Journal of Haematology*, **2004**, 124, 275-88	4.5	57
50	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. *Leukemia*, **2018**, 32, 1338-1348	10.7	56

49	Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. *International Journal of Oncology*, **2008**, 33, 239-44	1	50
48	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. *Blood*, **2011**, 118, 4188-98	2.2	48
47	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. *British Journal of Haematology*, **2016**, 175, 226-236	4.5	43
46	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. *Journal of Clinical Investigation*, **2014**, 124, 1512-24	15.9	42
45	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. *Leukemia*, **2014**, 28, 1252-1258	10.7	38
44	Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. *Journal of the National Cancer Institute Monographs*, **2008**, 52-7	4.8	37
43	MicroRNA expression in acute myeloid leukemia. *Current Hematologic Malignancy Reports*, **2009**, 4, 83-8	4.4	36
42	Molecular signatures in acute myeloid leukemia. *Current Opinion in Hematology*, **2009**, 16, 64-9	3.3	35
41	inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. *Blood*, **2013**, 121, 385-91	2.2	34
40	Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. *Leukemia*, **2019**, 33, 2169-2182	10.7	33
39	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. *Leukemia*, **2019**, 33, 1620-1634	10.7	30
38	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. *Haematologica*, **2014**, 99, 308-13	6.6	28
37	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E4641-E4647	11.5	25
36	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged . *Leukemia*, **2020**, 34, 3215-3227	10.7	24
35	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. *Haematologica*, **2017**, 102, 1391-1400	6.6	23
34	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. *Leukemia*, **2018**, 32, 2536-2545	10.7	22
33	MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 239-48	4.2	21
32	Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization. *Genes Chromosomes and Cancer*, **2003**, 38, 249-52	5	21

31	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. *Blood Advances*, **2020**, 4, 696-705	7.8	21
30	Randomized trial of 10 days of decitabine bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). *Blood Advances*, **2018**, 2, 3608-3617	7.8	20
29	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Haematologica*, **2011**, 96, 1488-95	6.6	19
28	Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. *American Journal of Hematology*, **2017**, 92, 388-396	7.1	17
27	Clinical and functional significance of circular RNAs in cytogenetically normal AML. *Blood Advances*, **2020**, 4, 239-251	7.8	16
26	Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. *Cancer Research*, **2017**, 77, 207-218	10.1	15
25	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 26340-26346	11.5	14
24	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). *Cancer Medicine*, **2018**, 7, 4447-4455	4.8	13
23	New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. *Genes Chromosomes and Cancer*, **2013**, 52, 385-401	5	13
22	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. *International Journal of Oncology*, **2002**, 21, 1041-51	1	13
21	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. *Cancer Discovery*, **2021**, 11, 626-637	24.4	11
20	Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). *Haematologica*, **2016**, 101, 1516-1523	6.6	10
19	Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions. *Clinical Cancer Research*, **2006**, 12, 3564s-71s	12.9	9
18	Spectral karyotyping reveals 17;22 fusions in a cytogenetically atypical dermatofibrosarcoma protuberans with a large marker chromosome as a sole abnormality. *Genes Chromosomes and Cancer*, **2001**, 31, 182-6	5	9
17	Mutations associated with a 17-gene leukemia stem cell score and the scores prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. *Haematologica*, **2020**, 105, 721-729	6.6	7
16	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. *Clinical Cancer Research*, **2019**, 25, 6524-6531	12.9	5
15	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). *Blood Advances*, **2021**, 5, 2481-2489	7.8	5
14	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. *Blood Advances*, **2021**, 5, 1474-1482	7.8	4

List of Publications

13	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. *Molecular Cancer Therapeutics*, **2019**, 18, 1451-1459	6.1	3
12	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). *Blood Advances*, **2021**, 5, 2775-2787	7.8	3
11	Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance **2015**, 275-317		2
10	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. *Leukemia*, **2020**, 34, 358-368	10.7	2
9	Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. *Journal of Hematology and Oncology*, **2021**, 14, 107	22.4	2
8	Acute myeloid leukemia with adverse cytogenetic risk. *Oncology*, **2012**, 26, 714, 723	1.8	1
7	Molecular associations, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (Alliance). *Blood Advances*, **2021**,	7.8	1
6	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. *Haematologica*, **2021**,	6.6	1
5	Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?. *Leukemia*, **2019**, 33, 809-810	10.7	0
4	Reply to K. Orendi et al. *Journal of Clinical Oncology*, **2013**, 31, 2361-2	2.2	0
3	Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience **1992**, 33, 239		
2	Acute Myeloid Leukemia **2016**, 527-559		
1	Albert de la Chapelle-pro memoriam. *Journal of Applied Genetics*, **2021**, 62, 455-458	2.5	